Anthrax Vaccine Market – By Type (Cell Free PA Vaccine [Absorbed, Precipitated], Live Attenuated Vaccine), Application (Human Use, Veterinary Use), End-use (Veterinary Hospitals & Clinics, Hospital & Clinics) & Forecast (2024 – 2032)

Anthrax Vaccine Market Size

Anthrax Vaccine Market was valued at USD 11.9 billion in 2023 and is anticipated to witness a CAGR of 5.4% over the analysis period. One of the primary drivers is the increasing awareness about anthrax as a potential bioterrorism threat, which has led to government initiatives and funding for anthrax vaccine development and procurement.
 

Additionally, the growing incidence of anthrax in livestock and humans, particularly in regions where the disease is endemic, is driving the demand for vaccines. Furthermore, the inclusion of anthrax vaccines in national immunization programs in some countries and the expansion of these programs to include more regions are expected to further fuel market growth.
 

Anthrax is a serious infectious disease caused by the bacterium Bacillus anthracis. It primarily affects animals but can also infect humans. Anthrax vaccines provide immunity against anthrax. The vaccines are generally safe and effective, although they can cause mild side effects such as soreness at the injection site, fever, and muscle aches.
 

Anthrax Vaccine Market Trends

• The global burden of anthrax is a significant concern, with estimates indicating a substantial impact on both human and livestock populations.
   
• Studies suggest that anthrax remains a disease of public health importance, particularly in regions with agricultural economies, where multiple outbreaks have demonstrated high morbidity and low mortality rates. For instance, in July 2022, Croatia reported an outbreak of anthrax infections. There were 17 reported human cases of cutaneous anthrax and 29 laboratory-confirmed animal cases.
   
• Additionally, the increasing incidence of anthrax in humans, particularly in regions where the disease is endemic or where there is a higher risk of exposure, has led to a greater demand for anthrax vaccines.
   
• Governments, public health agencies, and biopharmaceutical companies are therefore focusing on the development and distribution of anthrax vaccines to protect populations at risk, thereby stimulating the growth of the market.
   

Anthrax Vaccine Market Analysis

Based on type, the anthrax vaccine industry is segmented into cell free PA vaccine and live attenuated vaccine. The cell free PA vaccine is further divided into anthrax vaccine absorbed (AVA) and anthrax vaccine precipitated (AVP). The cell free PA vaccine segment dominated the market in 2023 and accounted for USD 6.7 billion.
 

• Cell free PA vaccine offers advantages such as improved safety profiles compared to whole-cell vaccines, as they do not contain live or attenuated bacteria.
   
• Additionally, cell-free PA vaccines are often more stable and easier to manufacture, making them more cost-effective for manufacturers. They also have shown promising results in providing immunity against anthrax, further driving their adoption.
   
• Thus, with increasing concerns about bioterrorism and the need for effective vaccines, the cell-free PA vaccine segment is expected to continue its dominance in the anthrax vaccines market.

Based on application, the anthrax vaccine market is segmented into veterinary use and human use. The veterinary use segment dominated the market with 81.8% of market share in 2023.
 

• Anthrax is a highly contagious and potentially fatal disease that affects animals, particularly livestock such as cattle, sheep, and goats.
   
• Vaccination is crucial for preventing the spread of anthrax in animal populations, protecting both animals and humans from the disease.
   
• Hence, the veterinary sector, including livestock producers, veterinarians, and government agencies, invest heavily in anthrax vaccines to safeguard animal health and ensure the safety of the food supply.
   
• Additionally, anthrax is considered a potential biological weapon, making it a priority for governments to vaccinate livestock as part of biosecurity measures.
   
• This heightened awareness and the necessity for vaccination programs contribute to the significant market share of the veterinary use segment in the anthrax vaccines market.
   

Based on end-use, the market is segmented into veterinary hospitals & clinics, hospital & clinics, and other end-users. The veterinary hospitals & clinics segment held highest market share in 2023 and is anticipated to grow at a CAGR of 5.5% over the forecast years.
 

• Veterinary hospitals and clinics are essential for the diagnosis, treatment, and prevention of anthrax in animals, making them primary points of contact for vaccination.
   
• These facilities play a crucial role in implementing vaccination programs, especially in regions where anthrax is endemic or poses a significant threat to livestock.
   
• Additionally, these institutions often have specialized equipment, trained staff, and established protocols for vaccine administration, ensuring the effective and safe delivery of anthrax vaccines to animals, further solidifying their market share as key end-users in the market.

North America anthrax vaccine market was valued at USD 4.7 billion in 2023 and is anticipated to reach USD 7.3 billion by 2032.
 

• Growing awareness among livestock animal caretakers regarding their immunization against anthrax is expected to positively impact regional growth over the forecast period.
   
• For instance, in May 2022, the South Dakota Animal Industry Board and Veterinarians from SDSU Extension urged cattle farmers to incorporate the anthrax vaccine into their immunization schedule when their cattle are let out to summer pastures in the spring.
   
• Additionally, the region's advanced healthcare infrastructure and high awareness levels among the populace contribute to the substantial uptake of anthrax vaccines, further solidifies North America's dominance in the market.
   

U.S. market is anticipated to grow at a CAGR of 5% between 2023 - 2032.
 

• The country's stringent regulatory framework ensures that only high-quality, approved vaccines are used, instilling confidence in both healthcare providers and the general population.
   
• Additionally, the U.S. has a robust biodefense program, which includes stockpiling anthrax vaccines for emergency use. This proactive approach to bioterrorism preparedness drives significant demand for anthrax vaccines in the country.
   
• Further, the presence of leading pharmaceutical companies with advanced research and development capabilities in the U.S. contributes to the availability of innovative vaccines and further strengthens the market's growth.
   

UK is anticipated to witness robust growth in the global anthrax vaccine market.
 

• UK's robust veterinary infrastructure, advanced research facilities, and strong government support for agriculture and livestock activities, position it as a key player in the market.
   
• Additionally, increasing awareness among healthcare professionals and the public about the threat of anthrax further fuels the demand for vaccines.
   

China anthrax vaccine industry is anticipated to witness lucrative growth between 2024 – 2032.
 

• The country's increasing focus on biosecurity and biodefense measures, coupled with a rising awareness of anthrax as a potential bioterrorism threat, has led to a growing demand for anthrax vaccines.
   
• Additionally, China's expanding livestock industry, particularly in regions where anthrax is endemic, has heightened the need for effective vaccines to protect animals and prevent economic losses.
   
• Furthermore, government initiatives aimed at strengthening public health infrastructure are expected to drive the adoption of anthrax vaccines in the coming years.
   

Anthrax Vaccine Market Share

The anthrax vaccine industry is characterized by the presence of several key players focusing on research, development, and commercialization of anthrax vaccines. Companies such as Emergent BioSolutions, Bavarian Nordic, and Elusys Therapeutics are among the prominent players in this market. These companies are actively engaged in developing innovative vaccines and enhancing their production capacities to meet the increasing demand for anthrax vaccines. Additionally, collaborations, partnerships, and acquisitions are common strategies adopted by these players to strengthen their market presence. The market is also witnessing the entry of new players, which is intensifying the competition and driving innovation in the development of anthrax vaccines.
 

Anthrax Vaccine Market Companies

Prominent players operating in the anthrax vaccine industry include:

• Altimmune Inc.
• Agrovet
• Bayer AG
• Bavarian Nordic
• Biogenesis Bago SA
• Ceva Sante Animale
• Colondo Serum Company
• Emergent BioSolutions
• Elusys Therapeutics Inc.
• Indian Immunologicals Ltd.
• Intervac (PVT) Ltd
• JOVAC
• Merck Co, Inc.
• Proton Biopharma Ltd.
   

Anthrax Vaccine Industry News:

• In January 2024, Emergent BioSolutions Inc. announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract to supply BioThrax for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease. This helped the company increase its sales.
   
• In July 2023, Emergent BioSolutions Inc. received the U.S. Food and Drug Administration (FDA) approval for CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age. This helped the company expand its product portfolio.
   

The anthrax vaccine market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Cell free PA vaccine
  • Anthrax vaccine absorbed (AVA)
  • Anthrax vaccine precipitated (AVP) 
• Live attenuated vaccine

Market, By Application

• Veterinary use
• Human use

Market, By End-use

• Veterinary hospitals & clinics
• Hospital & clinics
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa